Ilika’s Stereax Batteries: Powering the Next Heneration of Medical Devices - Part 2

Why It Matters

The partnership accelerates commercialization of ultra‑thin, long‑lasting batteries, unlocking recurring royalties for Ilika and enabling med‑tech firms to bring advanced implantable devices to market faster.

Key Takeaways

• MVP shipped; early orders indicate strong market traction.
• Customers range from multinationals to SMEs across orthopedics, neurostimulation.
• Integration into power management platforms essential for recurring royalty model.
• Cirtec partnership de‑risks scale‑up via thin‑film expertise and OEM links.
• Regulatory approval and volume ramp will shift profit share to royalties.

Summary

Ilika’s second‑part video outlines how its Stereax thin‑film batteries have moved beyond prototype to a minimum viable product that is already being shipped to customers. The announcement of an order for additional electrodes underscores early commercial traction and sets the stage for scaling.

Early adopters span large multinationals to innovative SMEs operating in smart orthopedics, neuro‑stimulation, implanted sensors, ophthalmic and orthodontic devices. The addressable market for active implantable medical devices is sizable, and Ilika expects a transition from component supplier to integrated power‑management platform, combining battery cells, management chips, power electronics and communications.

Ilika highlights the strategic partnership with Cirtec Medical, whose thin‑film manufacturing expertise and deep US OEM relationships provide a ready supply chain. As Ilika puts it, “Cirtec is the perfect partner… they have a technology base very similar to ours and strong relationships with medical device OEMs.” This collaboration is positioned to streamline regulatory approval and volume ramp‑up.

Once integrated platforms receive clearance, volume growth will shift Ilika’s revenue from an initial profit‑share to a royalty‑based model, delivering recurring income. The de‑risked scale‑up path promises faster adoption of long‑life, safe batteries across a new generation of implantable devices, potentially reshaping the med‑tech landscape.

Original Description

Ilika PLC (AIM:IKA, OTCQX:ILIKF, FRA:I8A) has begun shipping Stereax M300 prototypes to early customers.

In this segment, CEO Graeme Purdy explains the importance of the milestone, the types of medical applications the batteries are targeting and how partnerships such as Cirtec Medical could help bring the technology to market.

Watch the full interview on the Proactive website.

#MedTech #SolidStateBattery #Ilika #MedicalDevices #BatteryInnovation #HealthcareTechnology